
price close busi march
medic devic heart valv therapi includ
tissu valv mechan valv repair product
biomed devic servic
edward win reiter buy target goe
bottom line deliv superior surgeri savr thank extrem
low all-caus mortal stroke overal disabl stroke rate
one year think data give ew definit market advantag tavr
market rel whose evolut lr studi also hit non-inferior endpoint
discuss later report think higher hurdl clear
tavr data releas
plainli speak think data catalyz paradigm shift time
decision-mak process patient aortic stenosi favor tavr
vast major patient suffer sever symptomat ssa base
physician check wit think question go forward
patient tavr prefer choic impli case ssa patient
young tavr prefer treatment also compar savr
vs tavr savr arm respect paramount import
patient physician especi younger lower-risk patient
physician contact highlight low rate new-onset af tavr arm
vs savr cohort think emerg consequenti
endpoint time thu augment tavr adopt long term estim
competit standpoint think ew come leg
competit includ notwithstand evolut low-risk data slightli
rais ew tavr revenu estim believ data
augment adopt sapien tavr adopt expand especi us
sum think data coupl mdt low-risk data posit tavr
domin ssa patient popul near long term estim
patient us less penetr think data support
tavr ultim usurp surgeri standard care ssa patient cohort
follow compel data consequenti question investor
view fast fda grant indic expans lr patient popul
earlier guidance/street june/juli vs guidanc
think indic expans could come earli april/may accord check
regardless expect data drive uptick tavr util us
europ via ubiquit penetr intermediate-risk cohort coupl
risk creep low-risk cohort pre-ind expans approv think
market could acceler see low-risk tavr fda approv elicit indic
expans largest part tavr bell curv ssa market
low-risk approv repres largest market-expad catalyst tavr sinc
initi fda approv sapien extrem high-risk patient decad ago
reiter buy rate increas year-end target
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
superior establish one-year data ew
studi stellar exceed expect deliv superior top non-
inferior studi primari endpoint all-caus death stroke
rehospit one year rate all-cas death stroke
rehospit stood tavr arm vs savr arm
tavr demonstr superior savr deliv
reduct trial primari endpoint event rate tavr benefit savr
maintain across subgroup analys perform tavr favor across
three compon primari endpoint day one year
compellingli low one-year mortal stroke rate tavr ew
studi all-caus death one year impress low tavr
cohort vs savr arm even better one-year tavr mortal data
recent present lrt studi mortal one year stroke rate
one year equal impress vs savr arm
singl instanc disabl stroke tavr cohort
rate compar highli favor surtavi ir trial well
notion studi
evolut low-risk trial non-inferior valid tavr util low-risk
patient solid achiev studi primari endpoint comparison
stellar data data somewhat underwhelm view rate
all-cas death disabl stroke two year trial composit primari
endpoint stood tavr arm vs savr arm suffici
non-inferior specif though high ppm rate tavr cohort
vs savr arm elicit pushback use valv
specif younger patient firm latest valv use
patient receiv tavr major patient implant
evolutr like deliv lower ppm rate vs older-
gener valv still think data portend extrem posit sapien
util younger patient popul think data
substanti tavr place low-risk patient valid takeaway
lrt trial well strong data
rehospit defin cardiovascular rehospit
valve-rel procedure-rel includ hf rehospit
tavr cohort one year stood vs savr arm comparison
mdt trial look specif hospit heart failur alon
month follow hf-driven hospit tavr arm occur
patient vs savr cohort hospit re-admit repres initi
topic discuss follow present lrt data crt lrt re-
admit rate within day post-discharg stood includ due
cardiac complic latter repres posit metric panel
myriad definit rehospit gener trend seen across trial
portend posit tavr wed also note post procedur
tavr patient discharg home self-car vs
surgeri cohort tavr patient addit demonstr swifter improv
nyha classif walk test
secondari endpoint highlight ppm new-onset af beyond stellar
primari endpoint data tavr demonstr statist signific differ
new ppm rate vs tavr savr arm respect think
low ppm rate specif key lack pacemak placement
paramount younger patient low rate serv key driver
support convers surgeri tavr competit standpoint
buy unchang target price march
biomed devic servic
think data highlight strength platform vs competit platform
market support sapien adopt especi tavr expand
penetr younger patient cohort furthermor low rate
new-onset af tavr arm vs savr cohort
underappreci endpoint view tavr use deliv signific
posit impact patient outcom qualiti life
think tavr continu creep age curv averag age
patient treat tavr mdt low-risk trial
averag age lrt studi base past physician check
augment strong data set think tavr use ultim
expand penetr age curv tavr potenti
repres viabl option long term patient young
savr extend today year long-term tavr durabl
younger cohort given longer averag life expect group
imper metric continu follow think data long-term
follow-up intermedi risk ii surtavi trial provid
import initi look long-term tavr durabl said durabl data
around current surgic valv far mani physician
comment high-level observ view tavr valv market
today proven durabl long-last surgic valv option
paradigm shift decis make collect think data set
togeth lrt trial drive paradigm shift clinician
patient approach tavr vs savr decis make process futur
surgic risk tabl valv durabl patient life expect
becom key metric incorpor decision-mak process patient
specif prefer valu take greater posit tavr vs savr
discuss expect data set collect drive shift field
toward question tavr isnt appropri treatment option rather
patient transcathet approach make sens
econom valu proposit anoth win tavr neither data
present includ cost analysi clinician post-present
panel discuss doubt around tavr abil serv overal cost
saver healthcar system vs savr drive improv hospit
econom wed highlight ew prior tavr econom analysi data present
tct two year ago see note demonstr signific cost
benefit tavr savr intermedi risk patient provid one-two
punch clinic efficaci coupl cost effect support use
tavr savr patient cohort analysi look data tavr
arm well sapien compar
surgic arm cohort analysi encompass
cost relat re-hospit physician servic outpati cost well
rehab/skil nurs care result patient treat sapien
demonstr averag per patient lifetim cost save despit
higher up-front cost associ tavr coupl increas
overal save tavr arm larg driven reduct re-
hospit first year shorter simpler re-hospit
occur well reduct rehab/skil nurs cost think
data portend could eventu see low-risk cohort
incentiv shift toward tavr vs savr across board shift
discuss tavr appropri option rather tavr
use
what left tavr becom ubiquit think data
collect drive switch field toward question tavr isnt
buy unchang target price march
biomed devic servic
appropri key factor histor dissuad tavr placement shift
yesterday data present think tavr applic bicuspid valv
half low risk patient possess bicuspid valv remain outstand
question data compani help better defin
addit long-term valv leaflet function risk thrombosi remain key
low-risk approv timelin ew continu guid low-risk approv
year-end estimates/guid assum approv continu
expect fda grant approv expand indic ahead consensu
expect potenti earli next month especi base
superior demonstr mdt trial solidifi tavr
viabl altern surgeri low risk cohort early-approv would serv
upsid current estim
deriv price target appli price-to-earnings
pro forma ep
stock price compani discuss report
buy unchang target price march
biomed devic servic
lrttavrsavrtavrsavrtavrsavrtavrtavrsavrtavrsavrag /- /- /- /- /- /- /- /- /- /- st score /- /- /- /- /- /- /- /- /- /- /- caus pacemak sever onset valv risk p/e/g valuat financi metric use current mean large-cap medic devic price-to-earnings multipl ex outlier med-tech comp group ep compound-annual-growth-rate forward impli forma ep growth p/e/g multipl price-to-earnings multipl forma mo figur tavi
buy unchang target price march
biomed devic servic
symptomat patient year year year american age aortic age sever sever symptomat etiolog s/ ssa primari etiolog pe patient yr severe/symptomat ssa pe patient yr yr severe/symptomat ssa pe patient consid high risk surgeri consid intermedi risk surgeri consid risk surgeri consid high risk surgeri consid intermedi risk surgeri consid risk surgeri tavr market opportun tavr market opportun aortic stenosi elderli diseas preval number candid transcathet aortic valv replac meta-analysi model studi canaccord genuiti estim -conserv assum preval old age euroheart survey primari reason age lv canccord genuiti primari research ew compani report investor day assum ou market europe/japan us figur tavi ww market share
buy unchang target price march
biomed devic servic
edward lifesci averag implant center total unit total ew ww tavi revenu ex growth averag total unit total ww tavi revenu growth averag total unit total ww tavi revenu growth player ww tavi revenu ww implant patient popul player tavi ww revenu market lifesci implant averag implant total unit asp ew us revenu averag total unit asp total us revenu averag total unit asp us revenu player us revenu us implant address patient penetr us tavr market figur tavi eu/row market share
buy unchang target price march
biomed devic servic
detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact inform appear front page report
buy unchang target price march
biomed devic servic
million except per share revenu gross oper expens incom pre-tax incom tax interest exp eitf add-back net incom share ep forma ex ia margin analysi gross margin pro sale sale y/i revenu growth growth growth incom pro forma incom forma ex-one-tim ia figur revenu model
buy unchang target price march
biomed devic servic
heart valv aortic/mitr replacement/repairaort tavi sapien product royalti us total tavi mitral/trucuspid total tmvr/re total transcathet valv therapi surgic heart valv therapytissu repair surgic heart valv cardiac surgeri cardiac surgeri total surgic hv cs surgic valv consign total surgic hv/c revenu critic hemodynam pressur critic vascular vascular total critic vascular revenu pro forma total revenu figur revenu model part
buy unchang target price march
biomed devic servic
